The elucidation of antihyperglycemic action mechanism in the liver and pancreatic beta cells of bile acid resin

胆汁酸树脂在肝脏和胰腺β细胞中降血糖作用机制的阐明

• 批准号: 22590989
• 负责人: YAMAKAWA Tadashi
• 金额: $ 2.75万
• 依托单位: Yokohama City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22590989/
• 关键词: 胆汁酸; コレスチミド; 糖尿病; FXR; SHP; 糖脂質代謝; 膵β細胞

The objective of this study was to assess the chronic effects of a bile acid sequestrant, colestimide, on glucose metabolism in type 2 diabetes..Colestimide significantly reduced the elevated fasting blood glucose level, and CA even more markedly reduced fasting blood glucose. A hyperinsulinemic-euglycemic clamp study revealed that colestimide alleviated insulin resistance by suppressing hepatic glucose production and increasing peripheral glucose usage. Colestimide suppressed SHP expression, but enhanced SREBP2 expression. On the other hand, CA increased the expression of SHP and lipogenic enzymes such as ACC and SCD-1, but had no effect on SREBP2.

本研究的目的是评估胆汁酸螯合剂 Colestimide 对 2 型糖尿病患者葡萄糖代谢的慢性影响。Colestimide 显着降低升高的空腹血糖水平，CA 更显着降低空腹血糖。一项高胰岛素-正常血糖钳夹研究表明，考来司胺通过抑制肝葡萄糖产生和增加外周葡萄糖使用来减轻胰岛素抵抗。考来司胺抑制 SHP 表达，但增强 SREBP2 表达。另一方面，CA增加了SHP和脂肪生成酶如ACC和SCD-1的表达，但对SREBP2没有影响。